Imunon annual book value per share
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Imunon Book Value Per Share Growth & History (IMNN)
Imunon's book value per share was $2.07 for fiscal 2025.
View full Imunon company overviewImunon annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.07 | -$2.33 | −52.96% |
| 2024 | 2024-12-31 | $4.39 | -$16.97 | −79.45% |
| 2023 | 2023-12-31 | $21.36 | -$37.80 | −63.89% |
| 2022 | 2022-12-31 | $59.16 | -$85.88 | −59.21% |
| 2021 | 2021-12-31 | $145.04 | $42.15 | +40.97% |
| 2020 | 2020-12-31 | $102.88 | -$37.97 | −26.96% |
| 2019 | 2019-12-31 | $140.86 | -$108.39 | −43.49% |
| 2018 | 2018-12-31 | $249.25 | -$98.53 | −28.33% |
| 2017 | 2017-12-31 | $347.78 | -$330.80 | −48.75% |
| 2016 | 2016-12-31 | $678.58 | -$2,075.14 | −75.36% |
| 2015 | 2015-12-31 | $2,753.72 | -$2,420.35 | −46.78% |
| 2014 | 2014-12-31 | $5,174.08 | -$2,124.73 | −29.11% |
| 2013 | 2013-12-31 | $7,298.81 | $2,753.32 | +60.57% |
| 2012 | 2012-12-31 | $4,545.49 | $3,992.99 | +722.71% |
| 2011 | 2011-12-31 | $552.50 | $792.76 | — |
| 2010 | 2010-12-31 | -$240.26 | — | — |
Imunon quarterly book value per share
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $0.86 | $0.39 | +84.68% |
| Q4 2025 | 2025-12-31 | $2.07 | -$2.33 | −52.96% |
| Q3 2025 | 2025-09-30 | $1.41 | -$7.06 | −83.37% |
| Q2 2025 | 2025-06-30 | $1.55 | -$4.42 | −74.06% |
| Q1 2025 | 2025-03-31 | $0.46 | -$13.10 | −96.58% |
| Q4 2024 | 2024-12-31 | $4.39 | -$16.97 | −79.45% |
| Q3 2024 | 2024-09-30 | $8.47 | -$20.46 | −70.72% |
| Q2 2024 | 2024-06-30 | $5.97 | -$28.91 | −82.89% |
| Q1 2024 | 2024-03-31 | $13.56 | -$30.38 | −69.13% |
| Q4 2023 | 2023-12-31 | $21.36 | -$37.80 | −63.89% |
| Q3 2023 | 2023-09-30 | $28.94 | -$58.44 | −66.88% |
| Q2 2023 | 2023-06-30 | $34.88 | -$64.52 | −64.91% |
| Q1 2023 | 2023-03-31 | $43.94 | -$76.33 | −63.47% |
| Q4 2022 | 2022-12-31 | $59.16 | -$85.88 | −59.21% |
| Q3 2022 | 2022-09-30 | $87.38 | -$66.88 | −43.35% |
| Q2 2022 | 2022-06-30 | $99.40 | -$67.10 | −40.30% |
| Q1 2022 | 2022-03-31 | $120.26 | -$44.57 | −27.04% |
| Q4 2021 | 2021-12-31 | $145.04 | $42.15 | +40.97% |
| Q3 2021 | 2021-09-30 | $154.25 | $38.15 | +32.86% |
| Q2 2021 | 2021-06-30 | $166.50 | $2.59 | +1.58% |
| Q1 2021 | 2021-03-31 | $164.84 | $40.19 | +32.24% |
| Q4 2020 | 2020-12-31 | $102.88 | -$37.97 | −26.96% |
| Q3 2020 | 2020-09-30 | $116.10 | -$41.99 | −26.56% |
| Q2 2020 | 2020-06-30 | $163.92 | -$37.83 | −18.75% |
| Q1 2020 | 2020-03-31 | $124.65 | -$120.20 | −49.09% |
| Q4 2019 | 2019-12-31 | $140.86 | -$108.39 | −43.49% |
| Q3 2019 | 2019-09-30 | $158.09 | -$31.99 | −16.83% |
| Q2 2019 | 2019-06-30 | $201.75 | -$41.02 | −16.90% |
| Q1 2019 | 2019-03-31 | $244.85 | -$54.60 | −18.23% |
| Q4 2018 | 2018-12-31 | $249.25 | -$98.53 | −28.33% |
| Q3 2018 | 2018-09-30 | $190.08 | $47.69 | +33.49% |
| Q2 2018 | 2018-06-30 | $242.77 | -$10.17 | −4.02% |
| Q1 2018 | 2018-03-31 | $299.45 | -$47.32 | −13.65% |
| Q4 2017 | 2017-12-31 | $347.78 | -$330.80 | −48.75% |
| Q3 2017 | 2017-09-30 | $142.39 | -$1,135.49 | −88.86% |
| Q2 2017 | 2017-06-30 | $252.94 | -$1,764.59 | −87.46% |
| Q1 2017 | 2017-03-31 | $346.77 | -$1,711.89 | −83.16% |
| Q4 2016 | 2016-12-31 | $678.58 | -$2,075.14 | −75.36% |
| Q3 2016 | 2016-09-30 | $1,277.88 | -$2,153.25 | −62.76% |
| Q2 2016 | 2016-06-30 | $2,017.53 | -$1,967.57 | −49.37% |
| Q1 2016 | 2016-03-31 | $2,058.66 | -$2,148.11 | −51.06% |
| Q4 2015 | 2015-12-31 | $2,753.72 | -$2,420.35 | −46.78% |
| Q3 2015 | 2015-09-30 | $3,431.13 | -$2,705.64 | −44.09% |
| Q2 2015 | 2015-06-30 | $3,985.10 | -$3,173.98 | −44.34% |
| Q1 2015 | 2015-03-31 | $4,206.77 | -$3,213.86 | −43.31% |
| Q4 2014 | 2014-12-31 | $5,174.08 | -$2,124.73 | −29.11% |
| Q3 2014 | 2014-09-30 | $6,136.77 | — | — |
| Q2 2014 | 2014-06-30 | $7,159.07 | $6,781.50 | +1796.07% |
| Q1 2014 | 2014-03-31 | $7,420.63 | $6,975.85 | +1568.38% |
| Q4 2013 | 2013-12-31 | $7,298.81 | $2,753.32 | +60.57% |
| Q2 2013 | 2013-06-30 | $377.57 | $70.50 | +22.96% |
| Q1 2013 | 2013-03-31 | $444.78 | $15.69 | +3.66% |
| Q4 2012 | 2012-12-31 | $4,545.49 | $3,992.99 | +722.71% |
| Q3 2012 | 2012-09-30 | $262.04 | -$217.14 | −45.32% |
| Q2 2012 | 2012-06-30 | $307.08 | $289.69 | +1666.25% |
| Q1 2012 | 2012-03-31 | $429.09 | — | — |
| Q4 2011 | 2011-12-31 | $552.50 | $792.76 | — |
| Q3 2011 | 2011-09-30 | $479.18 | — | — |
| Q2 2011 | 2011-06-30 | $17.39 | — | — |
| Q4 2010 | 2010-12-31 | -$240.26 | — | — |
Imunon book value per share trends
Over the last five fiscal years, Imunon's book value per share decreased from $102.88 to $2.07, a change of -$100.82. The latest reported quarter, Q1 2026, shows $0.86.
About the metric
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
Calculation and source
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Imunon source filings ↗Community posts
IMUNON signs an NCI agreement to expand development of IMNN-001
IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and su ...